Skip to main content
. 2017 May 25;12(1):69–85. doi: 10.1080/19336918.2017.1319545

Figure 5.

Figure 5.

Pharmacological modulation of mechanical actin cytoskeleton properties affects the parameters of random migration. Migration experiments were performed without (control) or with inclusion of polymerized actin content-reducing compound Y-27632 (Y: 5 µM) or actomyosin activity inhibiting blebbistatin (Bl: 1 µM). In the case of shTcad-SMCs (purple) and shC-SMCs (blue) transductants (A-C), or actin polymerization-promoting compound LPA (L: 5 nM) in the case of Tcad+-SMCs (red) and E-SMCs (green) (D-F). Statistical analysis of MSD (A, D) and directionality ratio (B, E) was performed using nonlinear regression analysis. (A) Asterisked brackets indicate significant effects (P < 0.0001) of Bl or Y on the MSD of shTcad-SMCs compared with their untreated counterpart. (B) Asterisked brackets indicate significant effects (P < 0.0001) of either Bl or Y on shC-SMCs (purple bracket) and shTcad-SMCs (blue bracket) as compared with their own corresponding (untreated) control. Asterisked double arrowhead denotes significant differences (P < 0.0001) between shC-SMCs and shTcad-SMCs under each condition (untreated, + Bl or +Y). (D, E) Asterisked brackets indicate significant effects (P < 0.0001) of LPA on E-SMCs (green bracket) and Tcad+-SMCs (red bracket) as compared with their own corresponding (untreated) controls. Asterisked double arrowhead denotes significant a difference (*P < 0.05) between E-SMCs and Tcad+-SMCs in the presence of LPA. (C, F) One-way ANOVA followed by Tukey post-hoc testing was used for statistical analysis of velocity (*P < 0.05, ***P < 0.001, ns, not significant).